Douglas Loe
Leede Jones Gable
Douglas Loe, managing director and analyst at Leede Jones Gable, brings more than a decade of experience to financial analysis in the global drug development, medical technology, healthcare services and specialty pharmaceutical sectors. Loe has been recognized as one of Canada's top healthcare analysts by the StarMine Analysts Awards, based on the quality of his recommendations to institutional investors. He holds a Ph.D. in biochemistry.
Recent Articles
Testing Confirms Drug Candidate Differs From Peers 08/10/2022
Biotech ProMIS Neurosciences Inc.'s monoclonal antibody in development for Alzheimer's disease boasts a "unique" binding profile that could be "important to its clinical success," noted a Leede Jones Gable report.
Recent Quotes
"Updates on Alzheimer's by three biopharmas are pertinent to PMN."
—
Douglas Loe, Leede Jones Gable
(1/27/23)
more >
"AGN plans to initiate a Phase 2b trial of ifenprodil in chronic cough."
—
Douglas Loe, Leede Jones Gable
(1/13/23)
more >
"We expect PMN to commence formal Phase 1 testing later this year."
—
Douglas Loe, Leede Jones Gable
(1/6/23)
more >
"Data presented by peers at the CTAD conference are relevant to PMN."
—
Douglas Loe, Leede Jones Gable
(12/1/22)
more >
"RHT added 50 new nursing home clients in Florida to its network."
—
Douglas Loe, Leede Jones Gable
(11/4/22)
more >
"PMN peer, Eisai, reported positive Phase 3 Alzheimer's disease data."
—
Douglas Loe, Leede Jones Gable
(9/30/22)
more >
"We are positive about PMN's PMN-310 possibly mitigating AD progression."
—
Douglas Loe, Leede Jones Gable
(9/28/22)
more >
"Experiments showed that PMN's PMN310 has a unique binding profile."
—
Douglas Loe, Leede Jones Gable
(8/5/22)
more >
